Department of Obstetrics and Gynaecology, University of Melbourne, The Women's Hospital, Melbourne, Australia.
Gynaecological Research Centre, The Women's Hospital, Melbourne, Australia.
Nat Rev Dis Primers. 2020 Dec 10;6(1):98. doi: 10.1038/s41572-020-00228-z.
Recurrent pregnancy loss is a distressing pregnancy disorder experienced by ~2.5% of women trying to conceive. Recurrent pregnancy loss is defined as the failure of two or more clinically recognized pregnancies before 20-24 weeks of gestation and includes embryonic and fetal losses. The diagnosis of an early pregnancy loss is relatively straightforward, although progress in predicting and preventing recurrent pregnancy loss has been hampered by a lack of standardized definitions, the uncertainties surrounding the pathogenesis and the highly variable clinical presentation. The prognosis for couples with recurrent pregnancy loss is generally good, although the likelihood of a successful pregnancy depends on maternal age and the number of previous losses. Recurrent pregnancy loss can be caused by chromosomal errors, anatomical uterine defects, autoimmune disorders and endometrial dysfunction. Available treatments target the putative risk factors of pregnancy loss, although the effectiveness of many medical interventions is controversial. Regardless of the underlying aetiology, couples require accurate information on their chances of having a baby and appropriate support should be offered to reduce the psychological burden associated with multiple miscarriages. Future research must investigate the pathogenesis of recurrent pregnancy loss and evaluate novel diagnostic tests and treatments in adequately powered clinical trials.
复发性流产是一种困扰孕妇的妊娠疾病,约 2.5%的孕妇在妊娠 20-24 周前会经历这种情况。复发性流产是指两次或两次以上临床认可的妊娠在 20-24 周前失败,包括胚胎和胎儿损失。早期妊娠丢失的诊断相对简单,尽管由于缺乏标准化定义、发病机制的不确定性以及临床表现高度可变,预测和预防复发性流产的进展一直受到阻碍。对于复发性流产的夫妇来说,预后通常良好,尽管成功妊娠的可能性取决于母亲的年龄和以前的流产次数。复发性流产可由染色体错误、子宫解剖缺陷、自身免疫性疾病和子宫内膜功能障碍引起。现有的治疗方法针对流产的潜在危险因素,尽管许多医学干预措施的有效性存在争议。无论潜在病因如何,夫妇都需要了解他们生育的机会,并提供适当的支持,以减轻多次流产带来的心理负担。未来的研究必须调查复发性流产的发病机制,并在充分有力的临床试验中评估新的诊断测试和治疗方法。